FDA Panel Assesses Lilly Blood Thinner
For the last six years,
’s blood thinner Plavix has enjoyed a near monopoly in the market for oral medications meant to prevent clots in patients who are at risk for heart attacks and strokes.
That monopoly status could be threatened, if the
. Tuesday afternoon, an advisory panel may recommend that the F.D.A. grant that approval.
Plavix had global sales of $7.3 billion in 2007, making it the world’s second best-selling drug after
Read the rest of this entry »